Docetaxel
- Atc Codes:L01CD02
- CAS Codes:148408-66-6#114977-28-5
- PHARMGKB ID:148408-66-6#114977-28-5
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Docetaxel Winthrop, Ebedoce, Taxotere; Belgium: Taxotere; Bulgaria: Docetax; Cyprus: Taxotere; Czech Republic: Docetaxel Winthrop, Taxotere; Denmark: Taxotere; Estonia: Docetaxel Winthrop, Taxotere; Finland: Docetaxel Winthrop, Taxotere; France: Taxotere; Germany: Docetaxel Winthrop, Taxotere; Greece: Taxotere; Hungary: Docetaxel, Taxotere; Ireland: Docetaxel Winthrop, Taxotere; Italy: Taxotere; Latvia: Docetaxel Winthrop, Taxotere; Lithuania: Docetaxel Winthrop, Taxotere; Luxembourg: Docetaxel Winthrop, Taxotere; Malta: Docetaxel Winthrop, Taxotere; Netherlands: Docetaxel Winthrop, Taxotere; Poland: Docetaxel Winthrop, Taxotere; Portugal: Docetaxel Winthrop, Taxotere; Romania: Docetaxel Winthrop, Taxotere; Slovakia: Docetaxel Winthrop, Taxotere; Slovenia: Docetaxel Winthrop, Taxotere; Spain: Docetaxel Winthrop, Taxotere; Sweden: Docetaxel Winthrop, Taxotere; UK: Docetaxel Winthrop, Taxotere.
North America
Canada: Taxotere; USA: Taxotere.
Latin America
Argentina: Asodocel, Docekebir, Docetaxel, Dolectran NF, Donataxel, Doxetal, Plustaxano Anhidro, Taxotere, Texot, Trazoteva; Brazil: Docetaxel, Oncodocel, Taxotere, Trixotene; Mexico: Taxotere.
Asia
Japan: Taxotere.
Drug combinations
Docetaxel and Bevacizumab
Docetaxel and Cisplatin
Docetaxel and Cyclophosphamide
Docetaxel and Prednisone
Docetaxel and Thalidomide
Docetaxel and Trastuzumab
Docetaxel, Carboplatin, and Trastuzumab
Docetaxel, Cisplatin, and Fluorouracil
Docetaxel, Cisplatin, and Trastuzumab
Chemistry
Docetaxel: C~43~H~53~NO~14~ 3H~2~O. Mw: 861.93. (1) Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester trihydrate, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]]-; (2)(2R,3S)-N-Carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, trihydrate. CAS-148408-66-6; CAS-114977-28-5 (anhydrous)(1994).
Pharmacologic Category
Antineoplastic Agents; Plant Alkaloids and Other Natural Products; Antimicrotubular Agent. (ATC-Code: L01CD02).
Mechanism of action
A semisynthetic taxoid produced from the needles of the European yew (Taxus baccata L.) tree. Promotes the assembly of microtubules from tubulin dimers, and inhibits the depolymerization of tubulin which stabilizes microtubules in the cell, resulting in inhibition of DNA, RNA, and protein synthesis. Most activity occurs during the M phase of the cell cycle.
Therapeutic use
Used in combination with doxorubicin and cyclophosphamide for the adjuvant treatment of operable node-positive breast cancer. Docetaxel is used in combination with capecitabine for the treatment of metastatic breast cancer in disease that has failed anthracycline-containing chemotherapy. Docetaxel is also used as monotherapy for the second-line treatment of locally advanced or metastatic breast cancer after failure of prior chemotherapy. Used in combination with cisplatin as first-line therapy for unresectable, locally advanced or metastatic non-small cell lung cancer. Used in combination with prednisone for the treatment of androgen-independent (hormone-refractory) metastatic prostate cancer. Used in combination with cisplatin and fluorouracil for the initial treatment of advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction. Used in combination with cisplatin and fluorouracil as induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Pregnancy and lactiation implications
Docetaxel should be used during pregnancy only in life-threatening situations or in diseases for which safer drugs cannot be used or are ineffective. Not recommended during lactation.
Unlabeled use
Treatment of bladder cancer, ovarian cancer, small cell lung cancer, and soft tissue sarcoma.
Contraindications
Hypersensitivity to docetaxel or any component of the formulation. Hypersensitivity to medications containing polysorbate 80. Pre-existing bone marrow suppression (neutrophils <1500 cells/mm^3^).
Warnings and precautions
Patients must have recovered from acute toxicities of previous cytotoxic therapy before each cycle. Neutropenia occurs with doses of 60-100 mg/m^2^ and is dose-related. Severe fluid retention reported. Peripheral edema. Severe reactions, characterized by hypotension and/or bronchospasm or generalized rash/erythema, reported in some patients. Localized erythema of the extremities with edema followed by desquamation also reported. Patients often experience loss of all body hair, including axillary and pubic hair and that on the extremities, eyelashes, and eyebrows. Severe neurosensory symptoms (paresthesia, dysesthesia, pain) reported. Increased incidence of treatment-related mortality in abnormal liver function. Alopecia, myelosuppression (neutropenia, leukopenia, anemia), fluid retention, neurosensory effects, nausea, diarrhea, stomatitis are common adverse effects.